Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04707300
PHASE1/PHASE2

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

Sponsor: Assistance Publique - Hôpitaux de Paris

View on ClinicalTrials.gov

Summary

This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.

Official title: A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies

Key Details

Gender

All

Age Range

18 Years - 66 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2022-02-16

Completion Date

2028-08

Last Updated

2025-11-20

Healthy Volunteers

No

Interventions

DRUG

Human T Lymphoid Progenitor (HTLP) injection

The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0

Locations (5)

Hôpital Saint Louis

Paris, France

Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux

Pessac, France

IUCT Oncopole Toulouse

Toulouse, France

Institut Gustave Roussy

Villejuif, France

Hematology department / Necker Children's Hospital

Paris, Île-de-France Region, France